BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23371794)

  • 1. Description of a bivalent cannabinoid ligand with hypophagic properties.
    Fernández-Fernández C; Decara J; Bermúdez-Silva FJ; Sánchez E; Morales P; Gómez-Cañas M; Gómez-Ruíz M; Callado LF; Goya P; Rodríguez de Fonseca F; Martín MI; Fernández-Ruíz J; Meana JJ; Jagerovic N
    Arch Pharm (Weinheim); 2013 Mar; 346(3):171-9. PubMed ID: 23371794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
    Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
    J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Basis of Species-Dependent Differential Affinity of 6-Alkoxy-5-Aryl-3-Pyridinecarboxamide Cannabinoid-1 Receptor Antagonists.
    Iyer MR; Cinar R; Liu J; Godlewski G; Szanda G; Puhl H; Ikeda SR; Deschamps J; Lee YS; Steinbach PJ; Kunos G
    Mol Pharmacol; 2015 Aug; 88(2):238-44. PubMed ID: 26013543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and pharmacological evaluation of novel 4-alkyl-5-thien-2'-yl pyrazole carboxamides.
    Lazzari P; Pau A; Tambaro S; Asproni B; Ruiu S; Pinna G; Mastinu A; Curzu MM; Reali R; Bottazzi ME; Pinna GA; Murineddu G
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):254-76. PubMed ID: 22931442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationship of novel diarylpyrazole imide analogues as CB1 cannabinoid receptor ligands.
    Song KS; Kim MJ; Seo HJ; Lee SH; Jung ME; Kim SU; Kim J; Lee J
    Bioorg Med Chem; 2009 Apr; 17(8):3080-92. PubMed ID: 19328001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
    Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
    Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities.
    Thomas BF; Francisco ME; Seltzman HH; Thomas JB; Fix SE; Schulz AK; Gilliam AF; Pertwee RG; Stevenson LA
    Bioorg Med Chem; 2005 Sep; 13(18):5463-74. PubMed ID: 15994087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of CB1 cannabinoid receptor ligands derived from the 1,5-diarylpyrazole scaffold.
    Tu G; Xiong F; Huang H; Kuang B; Li S
    J Enzyme Inhib Med Chem; 2011 Apr; 26(2):222-30. PubMed ID: 20565336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Fubinaca/Rimonabant hybrids as endocannabinoid system modulators.
    Stefanucci A; Macedonio G; Dvorácskó S; Tömböly C; Mollica A
    Amino Acids; 2018 Nov; 50(11):1595-1605. PubMed ID: 30145711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier.
    Receveur JM; Murray A; Linget JM; Nørregaard PK; Cooper M; Bjurling E; Nielsen PA; Högberg T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):453-7. PubMed ID: 20015647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity.
    Katoch-Rouse R; Pavlova OA; Caulder T; Hoffman AF; Mukhin AG; Horti AG
    J Med Chem; 2003 Feb; 46(4):642-5. PubMed ID: 12570386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.
    Lange JH; van Stuivenberg HH; Coolen HK; Adolfs TJ; McCreary AC; Keizer HG; Wals HC; Veerman W; Borst AJ; de Looff W; Verveer PC; Kruse CG
    J Med Chem; 2005 Mar; 48(6):1823-38. PubMed ID: 15771428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-flavoured beverage in rats.
    Maccioni P; Pes D; Carai MA; Gessa GL; Colombo G
    Behav Pharmacol; 2008 May; 19(3):197-209. PubMed ID: 18469537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and in vitro evaluation of novel uni- and bivalent ligands for the cannabinoid receptor type 1 with variation of spacer length and structure.
    Huang G; Pemp D; Stadtmüller P; Nimczick M; Heilmann J; Decker M
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4209-14. PubMed ID: 25096297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity.
    Fulp A; Bortoff K; Seltzman H; Zhang Y; Mathews J; Snyder R; Fennell T; Maitra R
    J Med Chem; 2012 Mar; 55(6):2820-34. PubMed ID: 22372835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.
    Seo HJ; Kim MJ; Lee SH; Lee SH; Jung ME; Kim MS; Ahn K; Kim J; Lee J
    Bioorg Med Chem; 2010 Feb; 18(3):1149-62. PubMed ID: 20045337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of am 251, a cannabinoid CB1 receptor antagonist, on food intake in rats.
    Rutkowska M
    Acta Pol Pharm; 2004; 61(5):401-3. PubMed ID: 15747698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior.
    Duarte C; Alonso R; Bichet N; Cohen C; Soubrié P; Thiébot MH
    Neuropsychopharmacology; 2004 May; 29(5):911-20. PubMed ID: 14694354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor.
    Zhang Y; Gilliam A; Maitra R; Damaj MI; Tajuba JM; Seltzman HH; Thomas BF
    J Med Chem; 2010 Oct; 53(19):7048-60. PubMed ID: 20845959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel antiobesity agents: synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21.
    Alvarado M; Decara J; Luque MJ; Hernandez-Folgado L; Gómez-Cañas M; Gómez-Ruiz M; Fernández-Ruiz J; Elguero J; Jagerovic N; Serrano A; Goya P; de Fonseca FR
    Bioorg Med Chem; 2013 Apr; 21(7):1708-16. PubMed ID: 23434135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.